London
· Delayed Price · Currency is GBP · Price in USD Marinus Pharmaceuticals Statistics
Total Valuation
Marinus Pharmaceuticals has a market cap or net worth of GBP 24.42 million. The enterprise value is 67.46 million.
| Market Cap | 24.42M |
| Enterprise Value | 67.46M |
Important Dates
The next estimated earnings date is Thursday, March 6, 2025.
| Earnings Date | Mar 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +12.08% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 34.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.64 |
| EV / Sales | 2.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.78 |
Financial Position
The company has a current ratio of 1.66
| Current Ratio | 1.66 |
| Quick Ratio | 1.33 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.82 |
| Interest Coverage | -7.17 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -57.97% |
| Return on Capital (ROIC) | -79.94% |
| Revenue Per Employee | 141,426 |
| Profits Per Employee | -631,448 |
| Employee Count | 166 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 21.75 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.38% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -94.38% |
| 50-Day Moving Average | 0.37 |
| 200-Day Moving Average | 2.23 |
| Relative Strength Index (RSI) | 65.53 |
| Average Volume (20 Days) | 17,858 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.99 |
Income Statement
In the last 12 months, Marinus Pharmaceuticals had revenue of GBP 23.48 million and -104.82 million in losses. Loss per share was -1.84.
| Revenue | 23.48M |
| Gross Profit | -53.21M |
| Operating Income | -91.49M |
| Pretax Income | -104.82M |
| Net Income | -104.82M |
| EBITDA | -88.73M |
| EBIT | -91.49M |
| Loss Per Share | -1.84 |
Balance Sheet
The company has 31.47 million in cash and 71.02 million in debt, giving a net cash position of -39.55 million.
| Cash & Cash Equivalents | 31.47M |
| Total Debt | 71.02M |
| Net Cash | -39.55M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -49.79M |
| Book Value Per Share | -0.90 |
| Working Capital | 17.08M |
Cash Flow
In the last 12 months, operating cash flow was -85.61 million and capital expenditures -884,875, giving a free cash flow of -86.50 million.
| Operating Cash Flow | -85.61M |
| Capital Expenditures | -884,875 |
| Free Cash Flow | -86.50M |
| FCF Per Share | n/a |
Margins
| Gross Margin | -226.64% |
| Operating Margin | -389.70% |
| Pretax Margin | -446.49% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Marinus Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.08% |
| Shareholder Yield | -12.08% |
| Earnings Yield | -429.23% |
| FCF Yield | -354.20% |
Stock Splits
The last stock split was on September 23, 2020. It was a reverse split with a ratio of 0.25.
| Last Split Date | Sep 23, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.25 |
Scores
Marinus Pharmaceuticals has an Altman Z-Score of -18.88. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -18.88 |
| Piotroski F-Score | n/a |